Case Report: Two Rare Cases of Complete ...
Document type :
Compte-rendu et recension critique d'ouvrage
DOI :
Title :
Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
Author(s) :
Amrane, Karim [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Campedel, Luca [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Le Meur, Coline [Auteur]
CH Morlaix
Abgral, Ronan [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Kharroubi, Dris [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Cadranel, Jacques [Auteur]
Centre de référence maladies rares des maladies pulmonaires rares de l’adulte (CHU Dijon) [CRMR des maladies pulmonaires rares de l’adulte]
Hopital Saint-Louis [AP-HP] [AP-HP]
Campedel, Luca [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Le Meur, Coline [Auteur]
CH Morlaix
Abgral, Ronan [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Kharroubi, Dris [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Cadranel, Jacques [Auteur]
Centre de référence maladies rares des maladies pulmonaires rares de l’adulte (CHU Dijon) [CRMR des maladies pulmonaires rares de l’adulte]
Journal title :
Frontiers in Medicine
Publisher :
Frontiers media
Publication date :
2021-09-30
ISSN :
2296-858X
HAL domain(s) :
Sciences du Vivant [q-bio]/Ingénierie biomédicale/Médecine nucléaire
English abstract : [en]
Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common ...
Show more >Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[ 18 F] fluoro-D-glucose positron emission tomography-computed tomography ( 18 F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the 18 F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC.Show less >
Show more >Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[ 18 F] fluoro-D-glucose positron emission tomography-computed tomography ( 18 F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the 18 F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC.Show less >
Language :
Anglais
Popular science :
Non
Source :
Files
- https://hal.sorbonne-universite.fr/hal-03391339/document
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/file/fmed-08-691253.pdf
- Open access
- Access the document
- https://www.frontiersin.org/articles/10.3389/fmed.2021.691253/pdf
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/document
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/file/fmed-08-691253.pdf
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/document
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/file/fmed-08-691253.pdf
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/document
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/file/fmed-08-691253.pdf
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/document
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/file/fmed-08-691253.pdf
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/document
- Open access
- Access the document
- https://hal.sorbonne-universite.fr/hal-03391339/file/fmed-08-691253.pdf
- Open access
- Access the document
- Open access
- Access the document